Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

0579681 - BC 2024 RIV GB eng J - Článek v odborném periodiku
Salát, Jiří - Huňady, M. - Svoboda, Pavel - Strelcova, L. - Straková, Petra - Fořtová, A. - Palus, Martin - Růžek, Daniel
Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs.
Vaccine. Roč. 41, č. 42 (2023), s. 6150-6155. ISSN 0264-410X. E-ISSN 1873-2518
Grant CEP: GA MŠMT(CZ) LX22NPO5103
Institucionální podpora: RVO:60077344
Klíčová slova: louping-ill * Tickborne encephalitis * Vaccine * Dogs
Obor OECD: Virology
Impakt faktor: 5.5, rok: 2022
Způsob publikování: Omezený přístup
https://www.sciencedirect.com/science/article/pii/S0264410X23010897?via%3Dihub

Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tickborne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.
Trvalý link: https://hdl.handle.net/11104/0348493